Search Result

Results for "

HCV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (208) HCV Protease (39) Akt (2) Antibiotic (6) Apoptosis (2) Atg8/LC3 (1) Autophagy (4) Bacterial (5) Dengue virus (5) DNA/RNA Synthesis (15) Drug Metabolite (8) EGFR (2) Endogenous Metabolite (6) Enterovirus (6) Farnesyl Transferase (2) Flavivirus (5) Fluorescent Dye (1) Fungal (1) GLUT (2) HBV (12) Histamine Receptor (3) HIV (10) IFNAR (2) IKK (2) Influenza Virus (6) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (9) JAK (1) MicroRNA (3) Mitochondrial Metabolism (1) Nucleoside Antimetabolite/Analog (3) Orthopoxvirus (2) Parasite (5) PI4K (3) RAR/RXR (1) Reverse Transcriptase (4) RSV (7) SARS-CoV (28) SphK (1) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (3) Topoisomerase (6) TRP Channel (3) VEGFR (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (3) Endocrinology (2) Infection (215) Inflammation/Immunology (25) Metabolic Disease (8) Neurological Disease (2)
Click Chemistry:	Azide (9)

247

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: HCV HCV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138305

HCV-IN-31

HCV Infection Inflammation/Immunology

HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC₅₀/EC₉₅ of 15.7 μM for HCV replicon .
HY-144108

HCV-IN-35

HCV Infection

HCV-IN-35 (Compound (R)-3h) is a potent inhibitor of HCV. HCV-IN-35 has the potential for the research infection diseases .

HCV-IN-31	HCV	Infection Inflammation/Immunology
HCV-IN-31 (compound 4) is a *HCV* inhibitor, with an EC₅₀/EC₉₅ of 15.7 μM for HCV replicon .

HCV-IN-35	HCV	Infection
HCV-IN-35 (Compound (R)-3h) is a potent inhibitor of *HCV. HCV*-IN-35 has the potential for the research infection diseases .

HY-155832

HCV-IN-44	HCV	Infection
HCV-IN-44 (compound 28) is an HCV NS5B protein inhibitor that can effectively inhibit the replication of *HCV* virus. HCV-IN-44 can be used for the study of *HCV* infection .

HY-155831

HCV-IN-43	HCV	Infection
HCV-IN-43 (compound 2) is an HCV NS5B protein inhibitor that can effectively inhibit the replication of *HCV* virus. HCV-IN-43 can be used for the study of *HCV* infection .

HY-144110

HCV-IN-37	HCV	Infection
HCV-IN-37 (Compound 3d) is a potent inhibitor of *HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV*-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .

HY-133018

HCV-IN-7	HCV	Infection
HCV-IN-7 is an orally active and potent *pan-genotypic HCV* NS5A inhibitor with IC₅₀*s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV*-IN-7 has anti-viral activity .

HY-133018A

HCV-IN-7 hydrochloride	HCV	Cancer
HCV-IN-7 hydrochloride is an orally active and potent *pan-genotypic HCV* NS5A inhibitor with IC₅₀*s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV*-IN-7 hydrochloride has anti-viral activity .

HY-147763

HCV-IN-39	HCV	Infection
HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC₅₀ values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons .

HY-147764

HCV-IN-40	HCV	Infection
HCV-IN-40 (Compound 18c) is a potent, orally active hepatitis C virus (HCV) nucleoside inhibitor with EC₅₀ values of 0.259, 0.434 and 0.069 μM against GT1a, GT1b and GT1b CES1 replicons .

HY-P4035

HCV NS4A Protein (18-40) (JT strain)	HCV	Infection
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .

HY-115989

HCV-IN-38	HCV	Infection
HCV-IN-38 is a potent, selective and orally active *HCV* inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .

HY-147885

HCV-IN-41	HCV	Infection
HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC₅₀ value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .

HY-P4033

HCV Peptide (257-266)

HCV Infection Inflammation/Immunology

HCV Peptide (257-266) is a peptide. HCV Peptide (257-266) can be used for the research of hepatitis C virus (HCV) .
HY-P4031

HCV Peptide (131-140)

HCV Infection Inflammation/Immunology

HCV Peptide (131-140) is a peptide. HCV Peptide (131-140) can be used for the research of hepatitis C virus (HCV) .
HY-144106

HCV-IN-33

HCV Infection

HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor .

HCV Peptide (257-266)	HCV	Infection Inflammation/Immunology
HCV Peptide (257-266) is a peptide. HCV Peptide (257-266) can be used for the research of hepatitis C virus (HCV) .

HCV Peptide (131-140)	HCV	Infection Inflammation/Immunology
HCV Peptide (131-140) is a peptide. HCV Peptide (131-140) can be used for the research of hepatitis C virus (HCV) .

HCV-IN-33	HCV	Infection
HCV-IN-33 (Compound (S)-3i) is an *HCV* entry inhibitor .

HY-144107

HCV-IN-34	HCV	Infection
HCV-IN-34 (compound 3i) is an orally active and potent *HCV* entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC₅₀ of 0.010 μM and a CC₅₀ (half-maximal cytotoxic concentration) of 8.23 μM .

HY-18564

HCV-IN-3

HCV Infection

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC₅₀ of 20 μM, a K_d of 29 μM.
HY-136266

HCV-IN-29

HCV Cancer

HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e .

HCV-IN-3	HCV	Infection
HCV-IN-3 is a *hepatitis C virus (HCV) NS3/4a* protein inhibitor, with an IC₅₀ of 20 μM, a K_d of 29 μM.

HCV-IN-29	HCV	Cancer
HCV-IN-29 is a hepatitis C virus *(HCV)* inhibitor exacted from patent US8329159B2, compound 1e .

HY-144109

HCV-IN-36	HCV	Infection
HCV-IN-36 (compound (S)-3h) is an orally active and potent *HCV* entry inhibitor. HCV-IN-36 shows excellent antiviral activity, with an EC₅₀ of 0.016 μM and a CC₅₀ (half-maximal cytotoxic concentration) of 8.78 μM .

HY-136267

HCV-IN-30

HCV Infection

HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

HCV-IN-30	HCV	Infection
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

HY-P4037

HCV Core Protein (107-114)	HCV	Infection
HCV Core Protein (107-114) is a least immunogenic residue of the major linear *HCV* core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .

HY-P4036

HCV Core Protein (59-68)

HCV Infection

HCV Core Protein (59-68) is a peptide containing residues 59-68 of the HCV core protein .

HCV Core Protein (59-68)	HCV	Infection
HCV Core Protein (59-68) is a peptide containing residues 59-68 of the HCV core protein .

HY-P4029

HCV-1 e2 Protein (484-499)	HCV	Infection
HCV-1 e2 Protein (484-499) is a peptide consisting of 16 amino acids. HCV-1 e2 Protein (484-499) is derived from the envelope 2 protein of hepatitis C virus in the sera from individuals with antibodies to HCV .

HY-P4027

HCV-1 e2 Protein (554-569)	HCV	Infection
HCV-1 e2 Protein (554-569) is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) contains a putative n-glycosylation site, which was previously thought to influence the immune recognition of e2 .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P4027A

HCV-1 e2 Protein (554-569) (TFA)	HCV	Infection
HCV-1 e2 Protein (554-569) TFA is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) TFA contains a putative N-glycosylation site, which was previously thought to influence the immune recognition of e2 .

HY-14775

Nesbuvir

5+ Cited Publications

HCV-796
HCV Infection

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

Nesbuvir 5+ Cited Publications HCV-796	HCV	Infection
Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

HY-P0162

HCV-IN-4	HCV	Infection
HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC₉₀s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .

HY-50680

HCVP-IN-1

HCV Protease Infection

HCVP-IN-1 (compound 1) is a hepatitis C viral polymerase (HCVP) inhibitor .

HCVP-IN-1	HCV Protease	Infection
HCVP-IN-1 (compound 1) is a hepatitis C viral polymerase (HCVP) inhibitor .

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .

HY-111087

AZD-7295

HCV Protease Infection Inflammation/Immunology

AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

AZD-7295	HCV Protease	Infection Inflammation/Immunology
AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

HY-109047

Adafosbuvir AL-335	HCV DNA/RNA Synthesis	Infection
Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against *HCV* and acts as a potent inhibitor of HCV RNA polymerase .

HY-133248

Daclatasvir Impurity C

Drug Metabolite Others

Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
HY-133247

Daclatasvir Impurity B

Drug Metabolite Others

Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
HY-156051

Tetrazolast

HCV Infection

Tetrazolast is a HCV inhibitor with the inhibitory activity ranging from 5% to 20%, extracted from patent WO2005030774.

Daclatasvir Impurity C	Drug Metabolite	Others
Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

Daclatasvir Impurity B	Drug Metabolite	Others
Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

Tetrazolast	HCV	Infection
Tetrazolast is a *HCV* inhibitor with the inhibitory activity ranging from 5% to 20%, extracted from patent WO2005030774.

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside *hepatitis C virus (HCV) polymerase* inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside *hepatitis C virus (HCV) polymerase* inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-I0179

ITMN 4077

HCV Protease Infection

ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC₅₀: 2131 nM) .

ITMN 4077	HCV Protease	Infection
ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC₅₀: 2131 nM) .

HY-133246

Monodes(N-carboxymethyl)valine Daclatasvir Daclatasvir Impurity A	HCV	Infection
Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-15591

TMC647055	HCV	Infection
TMC647055 is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 can be used for the research of Hepatitis C virus (HCV) .

HY-P2502

Hepatitis Virus C NS3 Protease Inhibitor 2	HCV Protease HCV	Infection
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of *hepatitis C virus (HCV) NS3 protease, with a K_i* of 41 nM .

HY-15591A

TMC647055 Choline salt 1 Publications Verification	HCV	Infection
TMC647055 (Choline salt) is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 Choline salt has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 Choline salt can be used for the research of Hepatitis C virus (HCV) .

HY-148647

Mipomersen ISIS 301012 free base	HCV	Infection
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has *anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-101634

ABT-072

HCV Infection

ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

ABT-072	HCV	Infection
ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-126973

BI-1230	HCV Protease	Infection
BI-1230 is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication. BI-1230 is also highly selective against other serine/cysteine proteases. BI-1230 shows good Pharmacokinetic(PK) activity .

HY-147358A

Yimitasvir Emitasvir; DAG-181	HCV	Infection
Yimitasvir (Emitasvir) is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor. Yimitasvir can be used for research of chronic HCV infection .

HY-101634A

ABT-072 potassium trihydrate	HCV	Infection
ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-109035

Inarigivir soproxil 1 Publications Verification SB9200; GS-9992	HCV HBV	Infection
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant *HCV* variants, with EC₅₀s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .

HY-16593

GS-9256

HCV Protease Infection

GS-9256 is a selective HCV NS3 protease inhibitor. GS-9256 has good pharmacokinetic properties and antiviral activity .

HY-17470

Mizoribine 4 Publications Verification NSC 289637; HE 69	HCV SARS-CoV Antibiotic Parasite	Inflammation/Immunology
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits *HCV* RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

HY-L027

Antiviral Compound Library

1270 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

HY-L012

Metabolism/Protease Compound Library

4431 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases.

MCE designs a unique collection of 4431 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P4035

HCV NS4A Protein (18-40) (JT strain)	HCV	Infection
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .

HY-P4033

HCV Peptide (257-266)

HCV Infection Inflammation/Immunology

HCV Peptide (257-266) is a peptide. HCV Peptide (257-266) can be used for the research of hepatitis C virus (HCV) .
HY-P4031

HCV Peptide (131-140)

HCV Infection Inflammation/Immunology

HCV Peptide (131-140) is a peptide. HCV Peptide (131-140) can be used for the research of hepatitis C virus (HCV) .

HY-P4037

HCV Core Protein (107-114)	HCV	Infection
HCV Core Protein (107-114) is a least immunogenic residue of the major linear *HCV* core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .

HY-P4036

HCV Core Protein (59-68)

HCV Infection

HCV Core Protein (59-68) is a peptide containing residues 59-68 of the HCV core protein .

HY-P4029

HCV-1 e2 Protein (484-499)	HCV	Infection
HCV-1 e2 Protein (484-499) is a peptide consisting of 16 amino acids. HCV-1 e2 Protein (484-499) is derived from the envelope 2 protein of hepatitis C virus in the sera from individuals with antibodies to HCV .

HY-P4027

HCV-1 e2 Protein (554-569)	HCV	Infection
HCV-1 e2 Protein (554-569) is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) contains a putative n-glycosylation site, which was previously thought to influence the immune recognition of e2 .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P4027A

HCV-1 e2 Protein (554-569) (TFA)	HCV	Infection
HCV-1 e2 Protein (554-569) TFA is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) TFA contains a putative N-glycosylation site, which was previously thought to influence the immune recognition of e2 .

HY-P0162

HCV-IN-4	HCV	Infection
HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC₉₀s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .

HY-P5510

Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 HCV NS3 protease substrate	Peptides	Others
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructural protein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM. Upon cleavage of this substrate, fluorescence can be monitored at Abs/Em = 355/500 nm.)

HY-P2502

Hepatitis Virus C NS3 Protease Inhibitor 2	HCV Protease HCV	Infection
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of *hepatitis C virus (HCV) NS3 protease, with a K_i* of 41 nM .

HY-P4039

Ac-EEVVAC-pNA	HCV Protease	Infection
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .

HY-P3351

ASP5286

HCV Infection

ASP5286 is a novel non-immunosuppressive cyclophilin inhibitor for the research of HCV.

HY-12559

Alisporivir Maximum Cited Publications 14 Publications Verification Debio-025; DEB-025	HCV	Infection
Alisporivir (Debio-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity.

HY-P3590

PQDVKFP

HCV Others

PQDVKFP is a synthetic peptide, recognizing antigenic domains within the hepatitis C virus (HCV) core protein .

HY-P0025

NIM811 5+ Cited Publications (Melle-4)cyclosporin; SDZ NIM811	Mitochondrial Metabolism HCV	Infection Inflammation/Immunology
NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	VEGFR HCV Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

HY-P1934

Cyclo(Phe-Pro) 4 Publications Verification Cyclo(phenylalanylprolyl); A-64863	HCV	Infection
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17470

Mizoribine 4 Publications Verification NSC 289637; HE 69	Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields	HCV SARS-CoV Antibiotic Parasite
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits *HCV* RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-135867D

NHC-diphosphate 1 Publications Verification	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-diphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC is a pyrimidine ribonucleoside and behaves as a potent anti-virus agent. NHC effectively inhibits the replication of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV) .

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867

NHC-triphosphate	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867A

NHC-triphosphate tetrasodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-N7934

Trachelogenin (-)-Trachelogenin	Infection Monophenols Classification of Application Fields Source classification Lignans Phenols Amphimas pterocarpoides Harms Phenylpropanoids Plants Compositae Disease Research Fields Inflammation/Immunology	HCV
Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC₅₀ of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .

HY-N8188

Dehydrojuncusol	Infection Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	HCV HCV Protease
Dehydrojuncusol, a potent *HCV* inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35 µM) .

HY-N6798

Myriocin 4 Publications Verification Thermozymocidin; ISP-I	Infection Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	HCV Antibiotic
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 µg/mL for inhibiting HCV infection .

HY-W555382

Pseudane IX 2-Nonylquinolin-4(1H)-one	Structural Classification Alkaloids Ketones, Aldehydes, Acids Source classification Ruta graveolens Linn. Rutaceae Quinoline Alkaloids Plants	HCV
Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-N0588

Deapioplatycodin D	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields	HCV
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

HY-N3519

Platycodin D3	Infection Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields	HCV
Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

HY-N7672

Isoeuphorbetin	Infection Classification of Application Fields Gramineae Source classification Coumarins Phenols Polyphenols Leptochloa chinensis (Linn.) Nees Phenylpropanoids Plants Disease Research Fields	HCV Protease
Isoeuphorbetin, a dimeric coumarin isolated from Viola philippica, is a potent HCV protease inhibitor with an IC₅₀ of 3.63 µg/mL .

HY-N0620

Mulberroside C	Infection Monophenols other families Classification of Application Fields Source classification Phenols Plants Moraceae Disease Research Fields Morus alba Linn.	HCV
Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a HCV replicon inhibitor. Antiviral activity .

HY-N0248

Saikosaponin B2	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Umbelliferae Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	HCV
Saikosaponin B2 is an active component from Bupleurum chinensis root, acts as an entry inhibitor against HCV infection . Anti-cancer activity .

HY-N8520

Variculanol	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Bacterial
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-N3918

γ-Fagarine	Infection Alkaloids other families Classification of Application Fields Source classification Quinoline Alkaloids Plants Disease Research Fields	HCV
γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-HCV activities with IC₅₀ of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer .

HY-N7765

Oenothein B	Infection Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	HCV Bacterial Apoptosis Fungal
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .

HY-N6936

Sennidin A	Infection other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Plants Disease Research Fields	HCV Akt GLUT
Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	Cardiovascular Disease Structural Classification Classification of Application Fields Animals Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	VEGFR HCV Endogenous Metabolite
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

HY-N6935

Sennidin B	Infection other families Classification of Application Fields Leguminosae Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Metabolic Disease Plants Cassia angustifolia Disease Research Fields	HCV Akt GLUT
Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-120104

Nitidanin (±)-Nitidanin	Structural Classification Buxaceae Source classification Lignans Phenylpropanoids Plants Buxus microphylla S.et Z.var. Sinica Rehd.et Wils.	Parasite HCV
Nitidanin ((±)-Nitidanin) is an antimalarial and antiviral compound that can be isolated from the wood of Xanthoxylum nitidun D. C. Nitidanin is shows IC₅₀ values of 21.2 and 18.4 μM for D6 and W2 clones of Plasmodium falciparum, respectively. Nitidanin can be used for the research of malaria and virus infection .

HY-100313

YM-53601 free base	Structural Classification Alkaloids Carbazole Alkaloids	Farnesyl Transferase HCV
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates *HCV* propagation .

Species:	Virus (5)
Tag:	His (4) GST (1)
Source:	HEK293 (4) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74899

	*Envelope Glycoprotein E1 Protein, HCV* (HEK293, His)** HCV-E1 Protein; Hepatitis C virus Envelope Glycoprotein E1 / HCV-E1 (subtype 1b, strain HC-J4) Protein	Virus	HEK293
	Envelope Glycoprotein E1 Protein, one of two subunits of the envelope glycoprotein found in the hepatitis C virus, is a type 1 transmembrane protein. It associates with envelope glycoprotein E2 as a noncovalent heterodimer, which mediates virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds host apolipoproteins. And it also binds to CD81 and activates the epithelial growth factor receptor (EGFR) signaling pathway. Envelope Glycoprotein E1 Protein, HCV (HEK293, His) is the recombinant Virus-derived Envelope Glycoprotein E1 protein, expressed by HEK293 , with N-His labeled tag. The total length of Envelope Glycoprotein E1 Protein, HCV (HEK293, His) is 149 a.a., with molecular weight of ~18.7 kDa.

HY-P74184

E2/Envelope Protein, Hepatitis C virus (aa384-661, HEK293, His)

Hepatitis C virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His Tag); HCV-1a E2 Protein
Virus HEK293
HY-P74185

E2/Envelope Protein, Hepatitis C virus (278a.a, HEK293, His)

Hepatitis C virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His Tag); HCV-1a E2 Protein
Virus HEK293
HY-P74183

E2/Envelope Protein, Hepatitis C virus (HEK293, His)

HCV-1a E2 Protein; Hepatitis C virus (serotype 1b, isolate HC-J4) Envelope/E2 Protein
Virus HEK293

HY-P74898

	*NS3 protease Protein, HCV* (GST)** Hepatitis C virus (HCV-1a) NS3 protease / helicase immunodominant region Protein ( GST)	Virus	E. coli
	NS3 protease Protein is a zinc-dependent serine protease. NS3 needs to bind to the viral protein NS4A to enable additional conformation changes that enhance activity and appropriate intracellular localization. NS3 protein induces Caspase-8-mediated apoptosis independently of its protease or helicase activity. NS3 protease Protein, HCV (GST) is the recombinant Virus-derived NS3 protease protein, expressed by E. coli , with N-GST labeled tag. The total length of NS3 protease Protein, HCV (GST) is 104 a.a., with molecular weight of ~37.9 kDa.

Cat. No.	Product Name	Chemical Structure

HY-30234S

Clemizole-d4

Clemizole-d4 is a deuterium labeled Clemizole. Clemizole is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication .

HY-15005S1

Sofosbuvir-d6
Sofosbuvir-d₆ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-W011834S

2'-O-Methylcytidine-d3
2'-O-Methylcytidine-d₃ is deuterium labeled 2'-O-Methylcytidine (HY-W011834). 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.

HY-15005S

Sofosbuvir-13C,d3
Sofosbuvir- ¹³C,d₃ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-124592

BMT-052

BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-15236S

PSI-6206-13C,d3
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-141720S

N-Acetyl sulfadiazine-d4
N-Acetyl sulfadiazine-d₄ is the deuterium labeled Triton X-45(n=4). Triton X-45 (n=4), a nonionic surfactant with a low hydrophile-lypophile balance (HLB) value and dispersible in aqueous solution at room temperature, has a Krafft point above the room temperature. Triton X-45 has the potential for the research of the hepatitis C virus (HCV)[1][2].

HY-B0434S

Ribavirin-13C5

Ribavirin- ¹³C₅ is the ¹³C-labeled Ribavirin. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.

HY-10466S

Daclatasvir-d6
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

HY-10466S2

Daclatasvir-d16
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].

Cat. No.	Product Name		Classification

HY-19314A

Azvudine hydrochloride RO-0622 hydrochloride; FNC hydrochloride		Azide
Azvudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and *HCV*. Azvudine hydrochloride exerts highly potent inhibition on HIV-1 (EC₅₀s ranging from 0.03 to 6.92 nM) and HIV-2 (EC₅₀s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride inhibits NRTI-resistant viral strains . Azvudine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-19314

Azvudine RO-0622; FNC		Azide
Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and *HCV*. Azvudine exerts highly potent inhibition on HIV-1 (EC₅₀s ranging from 0.03 to 6.92 nM) and HIV-2 (EC₅₀s ranging from 0.018 to 0.025 nM). Azvudine inhibits NRTI-resistant viral strains . Azvudine is a click chemistry reagent, itcontains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine		Azide
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of *HCV. R-1479 inhibits HCV* replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626		Azide
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride		Azide
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-10870

RO-9187 5 Publications Verification		Azide
RO-9187 is a potent inhibitor of *HCV* virus replication with an IC₅₀ of 171 nM. RO-9187 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-77652

Nucleoside-Analog-2 1 Publications Verification		Azide
Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (HCV) replication. Nucleoside-Analog-2 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-139262

FNC-TP		Azide
FNC-TP is the intracellular active form of FNC. FNC is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and *HCV* . FNC-TP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-139262A

FNC-TP trisodium		Azide
FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and *HCV* . FNC-TP (trisodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks